Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Cancers|June 10, 2023
Peptide Receptor Radionuclide Therapy (PRRT): Innovations and ImprovementsElettra Merola, Chiara Maria Grana
Clinical Nuclear Medicine|September 9, 2016
Breast Cancer Incidentally Detected by 18F-Choline PET/CT in a Patient With Recurrent Prostate CarcinomaManuela Vadrucci, Laura Gilardi, Chiara Maria Grana
Neuroendocrinology|January 20, 2022
Tailored Molecular Imaging of Pheochromocytoma and Paraganglioma: Which Tracer and WhenGiuseppe Danilo Di Stasio, Vincenzo Cuccurullo, Giuseppe Lucio Cascini, et al.
Cancers|July 24, 2021
From the Magic Bullet to Theragnostics: Certitudes and Hypotheses, Trying to Optimize the Somatostatin ModelGiuseppe Danilo Di Stasio, Pasqualina Buonomano, Laura Lavinia Travaini, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 16, 2025
Theranostics in surgical oncologyS Stättner, Kjetil Soreide, Julie Hallet, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 29, 2022
Lymphopenia in patients affected by SARS-CoV-2 infection is caused by margination of lymphocytes in large bowel: an [18F]FDG PET/CT studyAlberto Signore, Chiara Lauri, Marzia Colandrea, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 5, 2009
The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: two cases of abnormal biodistributionDemetrio Aricò, Chiara Maria Grana, Anna Vanazzi, et al.
Cancer Treatment Reviews|April 24, 2018
Neuroendocrine neoplasms of rectum: A management updateEmilio Bertani, Davide Ravizza, Massimo Milione, et al.
Nuclear Medicine and Biology|February 4, 2010
Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin)Stefano Papi, Luigi Martano, Lucia Garaboldi, et al.
The British Journal of Surgery|August 30, 2024
Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II studyStefano Partelli, Luca Landoni, Mirco Bartolomei, et al.
Pageof 5